

# Vincent Chung

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2143633/publications.pdf>

Version: 2024-02-01

75  
papers

5,053  
citations

186209

28  
h-index

91828

69  
g-index

76  
all docs

76  
docs citations

76  
times ranked

7813  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients. <i>Journal of Palliative Medicine</i> , 2022, 25, 720-727.	0.6	22
2	B7H6 Serves as a Negative Prognostic Marker and an Immune Modulator in Human Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 814312.	1.3	5
3	First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2701-TPS2701.	0.8	10
4	Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2690-TPS2690.	0.8	7
5	The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1291-1302.	1.1	3
6	A Palliative Care Intervention for Patients on Phase 1 Studies. <i>Journal of Palliative Medicine</i> , 2021, 24, 846-856.	0.6	15
7	Chemotherapy-induced early transient increase and surge of CA 19â€9 level in patients with pancreatic Adenocarcinomaâ€. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100397.	0.7	1
8	Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. <i>Journal of Surgical Oncology</i> , 2021, 123, 1395-1404.	0.8	2
9	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	1.7	9
10	Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 4062.	1.7	7
11	Geriatric Assessmentâ€Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer. <i>JAMA Oncology</i> , 2021, 7, e214158.	3.4	213
12	Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa067.	1.4	7
13	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2020, 26, 5329-5337.	3.2	6
14	Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology. <i>Current Problems in Cancer</i> , 2020, 44, 100583.	1.0	4
15	Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies. <i>JAMA Network Open</i> , 2020, 3, e204787.	2.8	8
16	Dissemination and Implementation of Palliative Care in Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 995-1001.	0.8	17
17	Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. <i>Lancet Oncology</i> , The, 2020, 21, 508-518.	5.1	323
18	A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. <i>JAMA Oncology</i> , 2020, 6, 888.	3.4	293

#	ARTICLE	IF	CITATIONS
19	Spirituality in cancer patients on phase 1 clinical trials. <i>Psycho-Oncology</i> , 2020, 29, 1077-1083.	1.0	9
20	259â€¦Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC. , 2020, , .		1
21	Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 355-362.	2.7	11
22	Adjuvant chemotherapy versus chemoradiation in highâ€¦risk pancreatic adenocarcinoma: A propensity scoreâ€¦matched analysis. <i>Cancer Medicine</i> , 2019, 8, 5881-5890.	1.3	4
23	Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. <i>Cancer Treatment and Research Communications</i> , 2019, 21, 100155.	0.7	13
24	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2499-2511.	1.1	14
25	A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. <i>JAMIA Open</i> , 2019, 2, 505-515.	1.0	56
26	The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 462-473.	0.6	4
27	Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 978-986.	1.3	36
28	A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction. <i>Oncologist</i> , 2019, 24, 1137-1145.	1.9	2
29	Clinical Trials: Understanding Patient Perspectives and Beliefs About Treatment. <i>Clinical Journal of Oncology Nursing</i> , 2019, 23, 592-598.	0.3	7
30	Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	38
31	A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 589-598.	1.1	16
32	Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 202-210.	2.3	281
33	p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 1315-1325.	3.2	47
34	The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. <i>Familial Cancer</i> , 2018, 17, 235-245.	0.9	29
35	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to singleâ€¦agent checkpoint blockade. <i>Clinical and Translational Medicine</i> , 2018, 7, 32.	1.7	29
36	Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. <i>Clinical Cancer Research</i> , 2018, 24, 5018-5027.	3.2	158

#	ARTICLE	IF	CITATIONS
37	Targeted Therapies for Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 36.	1.7	69
38	Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. <i>Clinical Cancer Research</i> , 2017, 23, 3277-3284.	3.2	82
39	Current and future therapies for advanced pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 25-34.	0.8	123
40	Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy. <i>JAMA Oncology</i> , 2017, 3, 516.	3.4	142
41	Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. <i>Oncolmunology</i> , 2017, 6, e1363138.	2.1	20
42	Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1028-1061.	2.3	762
43	Characteristics of Participants Enrolled onto a Randomized Controlled Trial of Palliative Care for Patients on Phase I Studies. <i>Journal of Palliative Medicine</i> , 2017, 20, 1338-1344.	0.6	17
44	Goals-of-care discussions. <i>Journal of Community and Supportive Oncology</i> , 2017, 15, e190-e194.	0.1	11
45	A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. <i>Oncotarget</i> , 2017, 8, 83446-83456.	0.8	54
46	Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 962-969.	0.6	23
47	A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. <i>Oncotarget</i> , 2017, 8, 79750-79760.	0.8	12
48	Palliative Care and Phase 1 Trials: Intervention to Improve Quality of Life and Provide Education. , 2017, 21, 473-479.		11
49	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e1025-e1034.	2.5	83
50	Pilot study of an interdisciplinary supportive care planning intervention in pancreatic cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 3417-3424.	1.0	13
51	Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 921-927.	1.1	1
52	Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. <i>Oncology</i> , 2016, 90, 307-312.	0.9	8
53	Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. <i>Pancreas</i> , 2016, 45, 286-292.	0.5	12
54	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet</i> , 2016, 387, 545-557.	6.3	878

#	ARTICLE	IF	CITATIONS
55	<i>Salmonella</i>-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. <i>Cancer Immunology Research</i> , 2015, 3, 1096-1107.	1.6	58
56	Dietary alterations and restrictions following surgery for upper gastrointestinal cancers: Key components of a health-related quality of life intervention. <i>European Journal of Oncology Nursing</i> , 2015, 19, 343-348.	0.9	19
57	Systemic Therapy for Hepatocellular Carcinoma and Cholangiocarcinoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 187-198.	0.6	8
58	Feasibility of a Palliative Care Intervention for Cancer Patients in Phase I Clinical Trials. <i>Journal of Palliative Medicine</i> , 2014, 17, 1365-1368.	0.6	17
59	Overcoming immunosuppression to enhance a p53MVA vaccine. <i>Oncolmmunology</i> , 2014, 3, e958949.	2.1	10
60	Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: A retrospective review. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 83-87.	0.5	5
61	p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses. <i>Clinical Cancer Research</i> , 2014, 20, 4459-4470.	3.2	32
62	Pancreatic Adenocarcinoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1083-1093.	2.3	307
63	First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. <i>Investigational New Drugs</i> , 2013, 31, 986-1000.	1.2	187
64	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1089-1096.	1.1	24
65	Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2013, 19, 3631-3639.	3.2	59
66	Reply to adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer. <i>Cancer</i> , 2012, 118, 2185-2185.	2.0	0
67	First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 733-741.	1.1	65
68	A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP,) Tj ETQq0 0 0 rgBT /Overlock 1 <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 835-843.	1.1	35
69	Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer. <i>Cancer</i> , 2011, 117, 5493-5499.	2.0	24
70	Liver-Directed Regional Therapy in the Multi-Disciplinary Management of Hepatocellular Cancer. <i>Current Cancer Therapy Reviews</i> , 2010, 6, 19-25.	0.2	5
71	Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver. <i>Hpb</i> , 2008, 10, 396-404.	0.1	19
72	Symptom Concerns and Quality of Life in Hepatobiliary Cancers. <i>Oncology Nursing Forum</i> , 2008, 35, E45-E52.	0.5	56

#	ARTICLE	IF	CITATIONS
73	Phase II Study of Oxaliplatin in Patients With Unresectable, Metastatic, or Recurrent Hepatocellular Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 317-322.	0.6	38
74	SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 533-540.	1.9	3
75	High Mobility Group A2 Potentiates Genotoxic Stress in Part through the Modulation of Basal and DNA Damage-Dependent Phosphatidylinositol 3-Kinase-Related Protein Kinase Activation. <i>Cancer Research</i> , 2005, 65, 6622-6630.	0.4	51